Agilon Health, Inc. (NYSE: AGL) is a Healthcare company (Medical - Care Facilities) with a market capitalization of $2.0B. The Maz Rating grades it against the other companies in its sector.
Agilon Health, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $116.75, Agilon Health, Inc. trades at 0.3x sales and 7.0x book value. Over the last twelve months it generated about $6.0B of revenue and a net loss of $109M. It runs a gross margin of 2.8%, an operating margin of -1.8% and a net margin of -1.8%. It shows return on equity of -51.9%, return on invested capital of -31.6% and a free cash flow yield of -1.6%. On the balance sheet: a debt-to-equity ratio of 0.12 and a current ratio of 1.13. Over the past 52 weeks the share price ranged from $7.48 to $133.04, with a beta of 3.11.
Agilon Health, Inc. does not currently pay a dividend.
26 Wall Street analyst ratings cover the stock: 10 Buy, 14 Hold and 2 Sell, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
Agilon Health, Inc. provides healthcare solutions specifically designed for older adults, delivered through local primary care physicians throughout the United States. As of December 31, 2021, the company served an approximate total of 238,000 senior clients. This figure included 186,300 individuals enrolled in Medicare Advantage plans and 51,700 recipients of Medicare fee-for-service benefits. The enterprise, which commenced operations in 2016, was initially incorporated as Agilon Health Topco, Inc. before rebranding to its current name, agilon health, inc., in March 2021. Its corporate headquarters are situated in Austin, Texas.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Agilon Health, Inc. (AGL) passes 1 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, and fails S&P Global, Dow Jones, MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 1.99% / 30% · (Cash+Inv) / Mkt Cap (36m) 19.7% / 30% · Interest income / Revenue 0.00% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 1.99% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 15.6% / 33% · Receivables / Mkt Cap (36m) 66.1% / 49% · Interest income / Revenue 0.00% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 1.99% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 15.6% / 33.33% · Receivables / Mkt Cap (24m) 66.1% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 2.12% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 15.9% / 33.33% · Receivables / Avg Assets (4Q) 61.5% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 1.95% / 33.33% · (Cash+ST Inv) / Total Assets 15.3% / 33.33% · (Cash+Recv) / Total Assets 80.3% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Agilon Health, Inc. (AGL) passes 1 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, and fails S&P Global, Dow Jones, MSCI and FTSE.
Yes. Agilon Health, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
Agilon Health, Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.